SKAN Group (SKAN) H2 2024 earnings summary

Executive summary

• Order intake grew 21.8% year-over-year to CHF 359.5m, rebounding after slower growth in 2023, with a book-to-bill ratio of 1.0 and order backlog at CHF 318.3m.

• Net sales reached CHF 361.3m, up 12.9% year-over-year, slightly below guidance due to project shifts.

• EBITDA was CHF 57.0m with a margin of 15.8%, exceeding guidance despite high R&D investments.

• Investments totaled CHF 53.8m (+52.4%), mainly in pre-approved services and infrastructure expansion.

• Strong balance sheet with net cash position of CHF 43.1m and equity ratio at 52.7%.

Financial highlights

• Net sales increased 13% year-over-year to CHF 361 million.

• EBITDA margin improved to 15.8%, exceeding guidance.

• Operating cash flow improved from CHF 8.7m to CHF 46.7m, driven by profitability and working capital management.

• Return on capital margin increased from 19.7% to 21.5%.

• Dividend proposed at CHF 0.40 per share, up 14% from last year.

Outlook and guidance

• Net sales growth for 2025 guided in the mid-teens percentage range, with subdued H1 due to project delays and recovery anticipated in H2.

• Profitability guidance raised to 14-16% EBITDA margin, with gradual increase to upper teens mid-term.

• Project shifts expected to impact H1 2025, with stronger growth anticipated in 2026 as new orders convert to revenue.

• Structural growth drivers include pharmaceutical market expansion, injectable drug trends, and shift to isolator technology.